NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $22.00 -0.05 (-0.23%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$22.51 +0.51 (+2.32%) As of 08/8/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Indivior Stock (NASDAQ:INDV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Indivior alerts:Sign Up Key Stats Today's Range$21.88▼$22.4550-Day Range$12.46▼$22.0552-Week Range$7.33▼$22.45Volume2.19 million shsAverage Volume4.35 million shsMarket CapitalizationN/AP/E Ratio35.48Dividend YieldN/APrice Target$19.60Consensus RatingBuy Company Overview Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read More Indivior Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreINDV MarketRank™: Indivior scored higher than 31% of companies evaluated by MarketBeat, and ranked 778th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingBuy Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 3 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth40.16% Earnings GrowthEarnings for Indivior are expected to grow by 40.16% in the coming year, from $1.22 to $1.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 35.48, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 35.48, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.75.Read more about Indivior's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.89% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Indivior has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.89% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Indivior has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment0.69 News SentimentIndivior has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Indivior this week, compared to 6 articles on an average week.Search Interest7 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows1 people have added Indivior to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Stock News HeadlinesThe Street Loves This ‘Strong Buy’ Pharma StockAugust 8 at 6:04 PM | finance.yahoo.comIndivior (NASDAQ:INDV) Now Covered by HC WainwrightAugust 8 at 2:17 AM | americanbankingnews.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)Cannabis Stocks Worth Watching - August 6thAugust 8 at 2:23 AM | americanbankingnews.comIndivior Raises 2025 Guidance After Strong Q2 ResultsAugust 6 at 4:36 PM | theglobeandmail.comIndivior (INDV) Q2 EPS Jumps 104%August 6 at 4:36 PM | theglobeandmail.comIndivior initiated with a Buy at H.C. WainwrightAugust 6 at 4:36 PM | msn.comHC Wainwright & Co. Initiates Coverage of Indivior (INDV) with Buy RecommendationAugust 6 at 4:36 PM | msn.comSee More Headlines INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $12.43 at the beginning of 2025. Since then, INDV stock has increased by 77.0% and is now trading at $22.00. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) issued its earnings results on Thursday, July, 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. The firm earned $302 million during the quarter, compared to analyst estimates of $239.43 million. Indivior had a negative trailing twelve-month return on equity of 86.28% and a net margin of 6.65%. Read the conference call transcript. Who are Indivior's major shareholders? Indivior's top institutional shareholders include Geode Capital Management LLC (1.14%), Acadian Asset Management LLC, VELA Investment Management LLC and Intech Investment Management LLC (0.04%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings7/31/2025Today8/09/2025Next Earnings (Estimated)10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INDV CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,051Year FoundedN/APrice Target and Rating Average Price Target for Indivior$19.60 High Price Target$27.00 Low Price Target$13.00 Potential Upside/Downside-10.9%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.62 Trailing P/E Ratio35.48 Forward P/E Ratio18.03 P/E GrowthN/ANet Income$2 million Net Margins6.65% Pretax Margin15.60% Return on Equity-86.28% Return on Assets16.26% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.76 Sales & Book Value Annual Sales$1.19 billion Price / SalesN/A Cash Flow$1.82 per share Price / Cash Flow12.11 Book Value($2.52) per share Price / Book-8.73Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.74 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:INDV) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.